Avistone Pharmaceuticals Secures $200 Million Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

Hong Kong ,Palo Alto ,California ,United States ,Massachusetts ,Singapore ,Beijing ,China ,Shan Fu ,Zhejiang ,Chinese ,Jun Gao ,Scott Lessne ,Ricky Sun ,David Liu ,Katera Mujadidi ,Jiaqi Zheng ,Hongbo Lu ,Hepeng Shi ,China National Medical Products Administration ,Bain Capital Life Sciences ,Pearl Biotechnology Co ,Investor Group ,Avistone Pharmaceuticals ,Vivo Capital ,Bain Capital ,Primavera Capital ,Pearl Biotechnology ,Breakthrough Therapy ,National Medical Products Administration ,Managing Partner ,Greater China ,Bain Capital Asia Private Equity ,Managing Director ,Bain Capital Life ,Capital Life Sciences ,Capital Private Equity ,For Vivo Capital ,Business Wire ,Technology ,Science ,Health ,Business ,Biotechnology ,